Free Trial

Evotec (EVO) Competitors

Evotec logo
$3.76 +0.05 (+1.21%)
As of 10:07 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

EVO vs. LNTH, RYTM, AXSM, TLX, CRSP, PCVX, CYTK, MTSR, ADMA, and KRYS

Should you be buying Evotec stock or one of its competitors? The main competitors of Evotec include Lantheus (LNTH), Rhythm Pharmaceuticals (RYTM), Axsome Therapeutics (AXSM), Telix Pharmaceuticals (TLX), CRISPR Therapeutics (CRSP), Vaxcyte (PCVX), Cytokinetics (CYTK), Metsera (MTSR), ADMA Biologics (ADMA), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.

Evotec vs. Its Competitors

Evotec (NASDAQ:EVO) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

5.8% of Evotec shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 2.0% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Evotec presently has a consensus price target of $5.93, suggesting a potential upside of 57.59%. Lantheus has a consensus price target of $131.20, suggesting a potential upside of 81.15%. Given Lantheus' stronger consensus rating and higher possible upside, analysts plainly believe Lantheus is more favorable than Evotec.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evotec
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Lantheus
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Lantheus has higher revenue and earnings than Evotec.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evotec$788.22M1.70-$212.18MN/AN/A
Lantheus$1.53B3.27$312.44M$3.5220.58

In the previous week, Lantheus had 13 more articles in the media than Evotec. MarketBeat recorded 20 mentions for Lantheus and 7 mentions for Evotec. Lantheus' average media sentiment score of 0.97 beat Evotec's score of 0.08 indicating that Lantheus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evotec
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lantheus
10 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Lantheus has a net margin of 16.55% compared to Evotec's net margin of -26.34%. Lantheus' return on equity of 36.99% beat Evotec's return on equity.

Company Net Margins Return on Equity Return on Assets
Evotec-26.34% -21.51% -10.54%
Lantheus 16.55%36.99%20.55%

Evotec has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500.

Summary

Lantheus beats Evotec on 13 of the 14 factors compared between the two stocks.

Get Evotec News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVO vs. The Competition

MetricEvotecMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.34B$2.49B$5.61B$9.42B
Dividend YieldN/A1.80%4.01%4.02%
P/E RatioN/A9.2228.3620.00
Price / Sales1.70580.60414.8086.63
Price / CashN/A165.2635.9658.29
Price / Book1.295.088.425.73
Net Income-$212.18M$30.99M$3.24B$258.18M
7 Day Performance-10.78%3.09%4.13%3.46%
1 Month Performance-1.18%14.27%12.22%14.30%
1 Year Performance-21.23%-1.13%34.98%18.46%

Evotec Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVO
Evotec
2.089 of 5 stars
$3.77
+1.2%
$5.93
+57.6%
-24.4%$1.34B$788.22M0.004,827News Coverage
LNTH
Lantheus
4.7007 of 5 stars
$83.06
+2.2%
$131.20
+58.0%
-36.9%$5.75B$1.53B23.60700Upcoming Earnings
RYTM
Rhythm Pharmaceuticals
3.2799 of 5 stars
$89.15
+2.8%
$91.00
+2.1%
+76.4%$5.67B$130.13M-31.73140
AXSM
Axsome Therapeutics
4.6892 of 5 stars
$112.33
+3.1%
$172.33
+53.4%
+19.2%$5.53B$385.69M-19.47380
TLX
Telix Pharmaceuticals
N/A$15.57
-2.5%
$22.33
+43.4%
N/A$5.27B$783.21M0.00N/ANews Coverage
CRSP
CRISPR Therapeutics
1.7603 of 5 stars
$56.42
-0.7%
$71.75
+27.2%
+17.2%$4.87B$37.31M-12.48460Analyst Forecast
Analyst Revision
PCVX
Vaxcyte
1.8571 of 5 stars
$36.38
+1.3%
$136.50
+275.2%
-57.5%$4.69BN/A-9.12160Positive News
CYTK
Cytokinetics
4.2443 of 5 stars
$38.58
+4.2%
$70.92
+83.8%
-34.3%$4.61B$18.47M-7.29250
MTSR
Metsera
N/A$42.47
+8.1%
$55.00
+29.5%
N/A$4.46BN/A0.0081Gap Down
ADMA
ADMA Biologics
3.8878 of 5 stars
$18.68
+0.9%
$27.67
+48.1%
+24.0%$4.46B$426.45M21.98530Positive News
KRYS
Krystal Biotech
4.8342 of 5 stars
$150.41
+1.5%
$213.75
+42.1%
-26.6%$4.35B$290.52M36.16210Analyst Forecast

Related Companies and Tools


This page (NASDAQ:EVO) was last updated on 7/23/2025 by MarketBeat.com Staff
From Our Partners